Ravulizumab is becoming a treatment of choice for aHUS in countries where access is funded. Though eculizumab will still have a part to play in aHUS treatment. So is Ravulizumab…
aHUS Awareness Day 2021 - Answers to FAQs Finding information about any rare disease is challenging, and perhaps more so for an ultra rare disease such as atypical hemolytic uremic…
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a controlled trial of patients selected to test withdrawal of…
Atypical HUS Research – What’s New? The aHUS Alliance Global Action team has created a virtual ‘library’ of publications that are aHUS-specific and are categorized by topics such as diagnosis, treatment, genetics, thrombotic microangiopathy (TMA), complement, transplant, pregnancy, and more.
Article No. 442 23 June 2021 Today NICE ( The National Institute for Health and Care Excellence) concluded its evaluation of ravulizumab for treating aHUS by publishing its Final Guidance…
Article No 441 18 June 2021 What topics and questions are likely to frame conversations about treating patients who have atypical HUS? Since aHUS diagnosis begins with ruling…
Article No. 440 11 June 2021 Sometimes aHUS alliances Global Action sees things written about aHUS on the internet which are not clear or wrong. Unintentionally misinforming or misleading. Seldom…
Article No. 433 9 May 2021 Each day there are tweets about aHUS on Twitter. Mostly clinicians informing clinicians about new articles on the subject. Recently two tweets were noticed…